Aberdeen Group’s Immunovant IMVT Stock Holding History

Aberdeen Group’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.8M	Sell	1,160,762 -23,360	-2%	-$605K	0.05%	314
2025 Q4	$30.1M	Buy	1,184,122 +202,318	+21%	+$4.51M	0.05%	318
2025 Q3	$15.8M	Buy	981,804 +137,099	+16%	+$2.22M	0.03%	509
2025 Q2	$13.5M	Buy	844,705 +25,228	+3%	+$381K	0.02%	528
2025 Q1	$14M	Buy	819,477 +287,367	+54%	+$6.01M	0.03%	479
2024 Q4	$13.2M	Buy	532,110 +53,353	+11%	+$1.51M	0.02%	456
2024 Q3	$13.6M	Buy	478,757 +78,035	+19%	+$2.3M	0.03%	459
2024 Q2	$10.6M	Buy	400,722 +213,086	+114%	+$6.06M	0.02%	502
2024 Q1	$6.06M	Sell	187,636 -140,070	-43%	-$5.11M	0.01%	637
2023 Q4	$13.8M	Buy	+327,706	New	+$12.1M	0.03%	483

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Aberdeen Group's IMVT Position: Q1 2026 in Review

Aberdeen Group reduced its Immunovant (IMVT) stake by 2% in Q1 2026, selling an estimated $605K and leaving 1,160,762 shares worth $28.8M. The position accounts for 0.05% of the portfolio, ranked #314.

Aberdeen Group first reported a position in IMVT in Q4 2023 and has held it in 10 quarters since. The position peaked at $30.1M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Aberdeen Group held 1,160,762 shares of Immunovant worth $28.8M as of Q1 2026.
Aberdeen Group sold 23,360 Immunovant shares in Q1 2026, an estimated $605K.
Immunovant made up 0.05% of Aberdeen Group's portfolio in Q1 2026, its #314 holding.
Aberdeen Group first reported a position in Immunovant in Q4 2023 and has held it in 10 quarters since.
Aberdeen Group's Immunovant position peaked at $30.1M in Q4 2025.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.